Boothbay Fund Management LLC Buys 249,756 Shares of Alector, Inc. (NASDAQ:ALEC)

Boothbay Fund Management LLC raised its holdings in shares of Alector, Inc. (NASDAQ:ALEC - Free Report) by 562.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 294,156 shares of the company's stock after purchasing an additional 249,756 shares during the period. Boothbay Fund Management LLC owned 0.30% of Alector worth $556,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Alector by 64.7% during the third quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company's stock valued at $12,716,000 after purchasing an additional 1,072,298 shares during the period. Barclays PLC grew its stake in shares of Alector by 132.4% in the third quarter. Barclays PLC now owns 176,800 shares of the company's stock valued at $824,000 after buying an additional 100,731 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in Alector in the 4th quarter valued at about $47,000. SG Americas Securities LLC boosted its stake in shares of Alector by 27.9% during the 4th quarter. SG Americas Securities LLC now owns 39,334 shares of the company's stock worth $74,000 after acquiring an additional 8,581 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of Alector by 24.2% in the third quarter. Jane Street Group LLC now owns 154,942 shares of the company's stock valued at $722,000 after purchasing an additional 30,180 shares during the last quarter. 85.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on ALEC shares. HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Alector in a report on Thursday, February 27th. Morgan Stanley reissued an "underweight" rating and set a $1.50 target price (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $3.50.

Alector Stock Up 6.6 %

Shares of NASDAQ ALEC traded up $0.08 during trading on Friday, reaching $1.30. The company had a trading volume of 1,281,778 shares, compared to its average volume of 805,773. Alector, Inc. has a 12 month low of $0.87 and a 12 month high of $6.78. The stock has a market cap of $128.81 million, a P/E ratio of -0.76 and a beta of 0.73. The company's fifty day moving average price is $1.23 and its 200-day moving average price is $2.23.

Alector (NASDAQ:ALEC - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The company had revenue of $54.24 million for the quarter, compared to analyst estimates of $20.41 million. As a group, equities analysts predict that Alector, Inc. will post -1.88 earnings per share for the current year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.